1. Home
  2. CFBK vs SABS Comparison

CFBK vs SABS Comparison

Compare CFBK & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$27.93

Market Cap

167.9M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.96

Market Cap

187.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFBK
SABS
Founded
1892
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.9M
187.6M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
CFBK
SABS
Price
$27.93
$3.96
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$29.00
$9.80
AVG Volume (30 Days)
50.2K
354.4K
Earning Date
02-11-2026
11-13-2025
Dividend Yield
1.29%
N/A
EPS Growth
21.79
N/A
EPS
2.49
N/A
Revenue
$50,724,000.00
$114,698.00
Revenue This Year
$39.98
N/A
Revenue Next Year
$10.47
N/A
P/E Ratio
$11.22
N/A
Revenue Growth
14.25
N/A
52 Week Low
$19.23
$1.00
52 Week High
$28.21
$6.60

Technical Indicators

Market Signals
Indicator
CFBK
SABS
Relative Strength Index (RSI) 72.29 56.92
Support Level $26.71 $3.80
Resistance Level $27.43 $4.19
Average True Range (ATR) 0.70 0.25
MACD 0.19 0.01
Stochastic Oscillator 92.30 70.51

Price Performance

Historical Comparison
CFBK
SABS

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: